Gage FH, Coates PW, Palmer TD, Kuhn HG, Fisher LJ, Suhonen JO, et al
Providers review chronic conditions, current medications, previous treatments, family history, nutrition, exercise habits, sleep quality, stress levels, and personal treatment goals
Personalized Treatment: Genetic Insights and Precision Dosing The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), FTO (rs9939609), and MC4R (rs17782313) variants that relate to GLP-1 and related signaling pathways
Phillips Aesthetics is an important factor for patients exploring treatment options
Eli Lilly and Companys #Triple #Agonist #Retatrutide #Delivers #Powerful #Weight #Loss in Pivotal Phase 3 TRIUMPH-1 Obesity Trial 28.3% #Weight #Loss (70.3 lbs), 45.3% Achieve 30% Reduction, Approaching Bariatric Surgery-Level Outcomes Eli Lilly and Company just reported powerful Phase 3 TRIUMPH-1 topline data for retatrutide, its investigational triple agonist (GIP/GLP-1/glucagon) obesity therapy and the numbers may redefine expectations in obesity medicine
